FENC | tickerfilter.com

Fundamental analysis

25%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.28%

1 Month

-12.01%

3 Months

-18.69%

6 Months

-40.17%

1 Year

-32.57%

2 Year

-19.39%

Key data

Stock price

$5.56

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$5.00 - $11.92

52 WEEK CHANGE

-$0.33

MARKET CAP

152.394 M

YIELD

N/A

SHARES OUTSTANDING

27.360 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/06/2024

BETA

0.74

PUBLIC FLOAT

AVERAGE 10 VOLUME

$79,516

AVERAGE 30 VOLUME

$97,254

Company detail

CEO: Rostislav Raykov
Region: US
Website: http://fennecpharma.com/
Employees: 30
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.

FENC - Fennec Pharmaceuticals Inc